Valproic Acid in the Complex Therapy of Malignant Tumors

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F10%3A6055" target="_blank" >RIV/00064203:_____/10:6055 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/10:6055
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Valproic Acid in the Complex Therapy of Malignant Tumors
Original language description
Valproic acid (VPA) has been used for epilepsy treatment since the 1970s. Recently, it was demonstrated that it inhibits histone deacetylases (HDAC), modulates cell cycle, induces tumor cell death and inhibits angiogenesis. The exact anticancer mechanisms of VPA remains unclear, but HDAC inhibition, extracellular-regulated kinase activation, protein kinase C inhibition, Wnt-signaling activation, proteasomal degradation of HDAC, downregulation of telomerase activity and DNA demethylation participate in its anticancer effect. Hyperacetylation of histones, as a result of HDAC inhibition, seems to be the most important mechanism of VPA's antitumor action. Preclinical data suggest that the anticancer effect of chemotherapy is augmented when VPA is used in combination with cytostatics. We have demonstrated the synergistic effects of VPA and cisplatin in neuroblastoma. Clinical trials in patients with malignancies are being conducted.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NR9522" target="_blank" >NR9522: Potentiation of cytostatics effects by valproic acid</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)